Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Rice, MD Anderson researchers refine technique for attacking hard-to-reach tumors

Rice, MD Anderson researchers refine technique for attacking hard-to-reach tumors

Short, customized carbon nanotubes have the potential to deliver drugs to pancreatic cancer cells and destroy them from within, according to researchers at Rice University and the University of Texas MD Anderson Cancer Center. [More]
New nanomedicine allows glaucoma patients to do away with daily eye drops

New nanomedicine allows glaucoma patients to do away with daily eye drops

Scientists from Nanyang Technological University (NTU) and the Singapore Eye Research Institute (SERI) have jointly developed a new nanomedicine that will allow glaucoma patients to do away with daily eye drops. [More]
New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anti-cancer drugs and are capable of introducing a "cocktail" of multiple drugs into cancer cells. [More]
Allergists warn e-smokers of unknown risks

Allergists warn e-smokers of unknown risks

Caveat emptor - or "buyer beware" holds true when it comes to the unknown health effects of e-cigarettes. An article in the June issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), examines risks, including the ongoing dependence on nicotine and the dual use of e-cigarettes and regular cigarettes. [More]
Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. [More]
Studies show mobile phones can cause allergic contact dermatitis in both children and adults

Studies show mobile phones can cause allergic contact dermatitis in both children and adults

Studies have identified mobile phones and related devices as sources of metal sensitization and potential causes of allergic contact dermatitis (ACD). [More]
Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US. [More]
Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014. [More]
CVD risk factors may differ between men and women with type 2 diabetes, shows study

CVD risk factors may differ between men and women with type 2 diabetes, shows study

Type 2 diabetes greatly increases a person's risk of developing cardiovascular disease (CVD). A new study showing that cardiovascular risk factors such as elevated blood pressure and cholesterol levels differ significantly between men and women is published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Nanogel heals burn wounds faster

Nanogel heals burn wounds faster

Researchers at the Institute of Bioengineering and Nanotechnology have developed a nanogel that can accelerate the healing of burn wounds to minimize the risk of infection and scarring. The technology is based on IBN’s proprietary self-assembling ultrashort peptide technology, which are short sequences of amino acids. [More]
New breakthrough offers easier way of detecting pathogenic bacteria outside clinical setting

New breakthrough offers easier way of detecting pathogenic bacteria outside clinical setting

The breakthrough, published in the journal Nature Materials, could offer an easier way of detecting pathogenic bacteria outside of a clinical setting and could be particularly important for the developing world, where access to more sophisticated laboratory techniques is often limited. [More]
Perrigo receives final approval from FDA for azelastine hydrochloride nasal spray ANDA

Perrigo receives final approval from FDA for azelastine hydrochloride nasal spray ANDA

Perrigo Company plc announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal spray (0.15%). [More]
Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Molecular imaging aims at the visualization of molecules or molecular events that occur at the cellular level. Clearly it also allows the possibility of looking inside the biochemical pathway at the cellular level and therefore enables us to look at the onset of diseases well before they are resolved into structural change. [More]
Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. [More]
Research on laser assisted drug delivery selected for April 2014 issue of LSM

Research on laser assisted drug delivery selected for April 2014 issue of LSM

Research conducted by Lindsay R. Sklar, M.D., Christopher T. Burnett, M.D., F.A.A.D., Jill S. Waibel, M.D., F.A.A.D., Ronald L. Moy, M.D., F.A.A.D., and David M. Ozog, M.D., F.A.A.D., was selected as Editor’s Choice for the April 2014 issue of Lasers in Surgery and Medicine. [More]
Form of baclofen works better at treating narcolepsy

Form of baclofen works better at treating narcolepsy

Neuroscientists at SRI International have found that a form of baclofen, a drug used to treat muscle spasticity, works better at treating narcolepsy than the best drug currently available when tested in mice. [More]
Bioengineers develop tool that reacts to chemical changes caused by cancer cells

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells. [More]
FDA-cleared BD MAX Enteric Bacterial Panel now available to detect bacterial pathogens

FDA-cleared BD MAX Enteric Bacterial Panel now available to detect bacterial pathogens

BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson and Company), announced today the availability of the FDA-cleared BD MAX Enteric Bacterial Panel for use on the BD MAX System. [More]
USPTO issues three new patents to Discovery Laboratories

USPTO issues three new patents to Discovery Laboratories

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent and Notices of Allowance for patents covering critical aspects of its KL4 surfactant and drug delivery technology platform. [More]
Phillips-Medisize enters into definitive agreement with Golden Gate Capital

Phillips-Medisize enters into definitive agreement with Golden Gate Capital

Phillips-Medisize Corporation today announced that it has entered into a definitive agreement under which Golden Gate Capital will acquire the Company from funds managed by Kohlberg & Company, L.L.C. [More]